首页> 美国卫生研究院文献>Saudi Journal of Ophthalmology >Surgical removal of inadvertent intralenticular sustained-release dexamethasone implant (ozurdex) and implant one-piece posterior capsule intraocular lens
【2h】

Surgical removal of inadvertent intralenticular sustained-release dexamethasone implant (ozurdex) and implant one-piece posterior capsule intraocular lens

机译:外科疏忽颅内持续释放的地塞米松植入物(Ozurdex)和植入物单件后胶囊眼镜透镜

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To report the therapeutic efficacy and results of an accidentally injected intralenticular sustained-release dexamethasone implant (Ozurdex) in a patient with macular edema secondary to diabetic macular edema. Dexamethasone intravitreal implant is an approved formulation in the management of macular edema. The most common adversarial effects are an elevation of intraocular pressure (IOP) and cataract, but the unintentional injection of the dexamethasone implant into the lens is a particularly rare event.We report a case of a 72-year-old man treated for resistant Diabetic macular edema (DME) with dexamethasone intravitreal implant (Ozurdex, Allergan, Inc., Irvine, CA, USA) in which the technique was complicated by accidental implantation into the lens body and review the management. The patient underwent phacoemulsification of the lens, removal of the Ozurdex, intravitreal Avastin injection, and implant of a one-piece lens in the posterior capsule.
机译:报告在患者中意外注入的颅内持续释放的地塞米松植入物(Ozurdex)的治疗疗效和结果,其具有糖尿病性黄斑水肿的黄斑水肿。地塞米松玻璃体植入植入物是在黄斑水肿的管理中批准的制剂。最常见的对抗性效果是眼内压(IOP)和白内障的升高,但无意地注射到镜片中的地塞米松注射到镜片中是一个特别珍稀的事件。我们报告了一个72岁男性用于抗性糖尿病的案例黄斑水肿(DME)与地塞米松intraviTem植入物(Ozurdex,Allergan,Inc.,Irvine,CA,USA),其中该技术因意外植入到镜片体中并审查管理而复杂化。患者接受晶状体乳化的晶状体,除去Ozurdex,玻璃体内阿瓦斯汀注射,并在后囊中的单件镜头植入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号